How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


PolySia avDP20

Organization name

PROvendis GmbH



There is no satisfactory therapy to prevent the loss of synapses, axons or neurons in neurodegenerative diseases, such as age-related macular degeneration (AMD), multiple sclerosis and Alzheimer’s disease. Several studies demonstrate that this neuronal damage is partly mediated by proinflammatory cytokines, overt complement activation and reactive oxygen species released by tissue macrophages and microglia.

The present invention allows preventing the production of proinflammatory cytokines, reactive oxygen species and overt complement activation through the application of low molecular weight polysialic acid with an average degree of polymerization of 20 (“PolySia avDP20”). In vitro studies showed that PolySia-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic proinflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11.

Further in vitro studies demonstrated that PolySia avDP20 prevented activation of the alternative complement pathway. In vivo studies revealed that the administration of PolySia avDP20 suppresses activation of retinal microglia and choroidal macrophages, inhibits vascular leakage and formation of the complement membrane attack complex in an animal model of AMD and reduces the disease symptoms in an animal model of multiple sclerosis. Thus, PolySia avDP20 represents an ideal candidate for treating neurodegenerative diseases of the retina and the brain.

Commercial Opportunities

The invention offers a novel approach for the prevention of inflammatory and complement-mediated neuronal damage in the course of AMD or other neurodegenerative diseases.

Current Status  

Inventors at the University Hospitals of Bonn and Cologne are seeking for a partnership for co-development of PolySia avDP20 for the treatment of dry AMD. On behalf of both institutions, PROvendis offers research collaboration with licensing Option.

Relevant Publications

Sharaz, A. et al. (2015). Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages. Sci. Rep. 5: 16800

Karlstetter, M. et al. (2016). Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation and protects from vascular damage in the retina. EMBO Mol. Med., in press

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries